New technologies in the interventional cardiology, angiology and electrophysiology should be included in the therapy for reasons of quality and financing through clinical trials.
In order to be able to offer our patients the most modern treatments, the Cardiovascular Center Klinikverbund Allgäu has a across location study office headed by Mrs. Jacqueline Fiedler.
Tel. 08323 910-8909
Fax 08323 910-128
jacqueline.fiedler@klinikverbund-allgaeu.de
Tel. 08323 910-8909
Fax 08323 910-128
andrea.zimmermann@klinikverbund-allgaeu.de
Tel. 08323 910-8909
Fax 08323 910-128
tina.kienle@klinikverbund-allgaeu.de
The RECording COurses of vasculaR Diseases registry (RECCORD registry) is an observational, prospective, multicentre, all-comers registry platform.
In the initial phase, patients referred for endovascular revascularization of peripheral artery disease (PAD) of the lower limbs will be prospectively included and followed up for at least one year.
The RECording COurses of vasculaR Diseases registry (RECCORD registry) is an observational, prospective, multicentre, all-comers registry platform.
In the initial phase, patients referred for endovascular revascularization of peripheral artery disease (PAD) of the lower limbs will be prospectively included and followed up for at least one year.
The objective of this prospective, randomized,controlled and multicenter trial is, to compare recurrent-restenosis rates in the balloon expandable VISIO-PRO stent arm and the selfexpandable PROTEGE GPS stent arm 12 month after treatment of stenosis or occlusions of common and external iliac artery disease
The ABSORB IV Randomized Controlled Trial (RCT) is designed to continue to evaluate the safety and effectiveness as well as the potential short and long-term benefits of Abbott Vascular Absorb™ Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System (once commercially available), as compared to the commercially approved, control stent XIENCE.
The ABSORB IV Randomized Controlled Trial (RCT) is designed to continue to evaluate the safety and effectiveness as well as the potential short and long-term benefits of Abbott Vascular Absorb™ Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System (once commercially available), as compared to the commercially approved, control stent XIENCE.
The ABSORB IV Randomized Controlled Trial (RCT) is designed to continue to evaluate the safety and effectiveness as well as the potential short and long-term benefits of Abbott Vascular Absorb™ Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System (once commercially available), as compared to the commercially approved, control stent XIENCE.
Interleukin-10 mRNA-Transfektion von Makrophagen zur anti inflammatorischen Therapie – proof of principle am Myokarditis-Modell der Maus (Interleukin-10 mRNA transfection of macrophages for anti-inflammatory therapy – proof of principle on the myocarditis model of the mouse)
DFG It 13/3-1: Untersuchungen zur Funktion des Zelladhasionsmoleküls CEACAM1 für die durch Inflammation vermittelte Gefäßzellaktivierung während des Kollateralwachstums (Investigations on the function of the cell adhesion molecule CEACAM1 for vascular cell activation mediated by inflammation during collateral growth)
This study evaluates the antithrombotic therapy in patients suffering from atrial fibrillation after stent implantation in Germany. Patients prescribed with the novel oral anticoagulant Rivaroxaban will be followed up over 14 months for their adherence to the medication schedule and for complications that occurred after index PCI
![[Bitte in "english" übersetzen:]](/fileadmin/_processed_/3/6/csm_Herz-Gefaesszentrum_Kliniken_b881e41a9d.jpg "[Bitte in \"english\" übersetzen:]")
